Copyright
©The Author(s) 2017.
World J Gastroenterol. Sep 14, 2017; 23(34): 6212-6219
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6212
Published online Sep 14, 2017. doi: 10.3748/wjg.v23.i34.6212
Table 1 Clinical baseline characteristics in frequencies n (%)
CRC patients | Others (survivors or deceased by other causes) | CRC specific mortality | P value | |
n = 174 | n = 134 (77) | n = 40 (23) | ||
Age | 70 (range 29-90) | 70 (29-90) | 72 (36-90) | 0.2641 |
Gender | 105 men (60) | 83 men (62) | 22 men (55) | 0.431 |
Localization | 105 colon (60) | 78 colon (58) | 27 colon (68) | 0.292 |
Cancer recurrence | 34 (20) | 16 (12) | 18 (45) | < 0.001 |
Radical surgery | 165 (95) | 130 (97) | 35 (88) | < 0.051 |
TNM stage I/II/III/IV | 24/54/67/29 (14/31/38/17) | 22/51/54/7 (17/38/40/5) | 2/3/13/22 (5/8/32/55) | < 0.0011 |
Preoperative treatment | 41 (24) | 36 (27) | 5 (13) | 0.0601 |
Adjuvant treatment | 71 (41) | 47 (35) | 24 (60) | 0.0051 |
Total mortality | 66 (38) | 26 (19) | 40 (100) | < 0.001 |
Table 2 Levels of inflammatory factors significantly associated to TNM stage
Factor | TNM stage I (n = 24), Median1 (range) | TNM stage II (n = 54), Median1 (range) | TNM stage III (n = 67), Median1 (range) | TNM stage IV (n = 29), Median1 (range) | P value |
CCL20 | 100 (77-242) | 119.5 (80-272) | 124 (89-183) | 149 (111-378) | 0.034 |
CCL27 | 11956 (9975-15131) | 11293 (8799-14133) | 10308 (8173-13923) | 9461 (7619-12283) | 0.035 |
IL-8 | 99 (81-439) | 113 (97-146) | 104 (85-153) | 166 (113-243) | 0.009 |
MIF | 19565 (13546-33372) | 23720 (14452-43786) | 21900 (14146-33330) | 47235 (20723-89267) | 0.031 |
Table 3 Total mortality and association with highest tertile level of inflammatory factors
Factor | Total mortality | Total mortality adjusted1 | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
Age | 1.0 (1.0-1.1) | 0.006 | 1.1 (1.0-1.1) | < 0.001 |
TNM stage II | 1.5 (0.5-4.0) | 0.464 | 1.2 (0.4-3.2) | 0.777 |
TNM stage III | 1.8 (0.7-4.8) | 0.228 | 2.2 (0.8-6.1) | 0.141 |
TNM stage IV | 6.8 (2.6-17.9) | < 0.001 | 14.6 (6.0-42.6) | < 0.001 |
Radical surgery | 0.2 (0.1-0.4) | < 0.001 | 0.3 (0.1-0.6) | 0.002 |
Preoperative treatment | 0.8 (0.4-1.5) | 0.454 | 0.7 (0.4-1.4) | 0.338 |
Adjuvant treatment | 1.1 (0.6-1.7) | 0.842 | 0.7 (0.4-1.3) | 0.226 |
CCL1 | 3.2 (1.7-5.9) | < 0.001 | 2.7 (1.4-5.4) | 0.004 |
CCL3 | 2.0 (1.1-3.6) | 0.030 | 1.2 (0.6-2.2) | 0.605 |
CCL15 | 2.3 (1.2-4.3) | 0.010 | 1.9 (1.0-3.7) | 0.046 |
CCL20 | 3.1 (1.6-6.0) | 0.001 | 2.2 (1.1-4.3) | 0.021 |
CCL26 | 1.7 (1.0-3.0) | 0.055 | 1.7 (0.9-3.0) | 0.078 |
CX3CL1 | 3.3 (1.8-6.1) | < 0.001 | 2.3 (1.2-4.5) | 0.014 |
CXCL1 | 1.9 (1.0-3.4) | 0.038 | 1.4 (0.8-2.6) | 0.295 |
CXCL10 | 2.1 (1.1-4.0) | 0.017 | 1.3 (0.7-2.6) | 0.387 |
CXCL13 | 1.8 (1.1-3.2) | 0.033 | 2.0 (1.0-3.7) | 0.039 |
CXCL16 | 1.6 (0.9-2.8) | 0.139 | 1.7 (0.9-3.1) | 0.113 |
IFN-γ | 3.1 (1.6-6.1) | 0.001 | 3.5 (1.6-7.5) | 0.001 |
IL-1β | 2.1 (1.2-3.8) | 0.012 | 1.7 (0.9-3.1) | 0.081 |
IL-2 | 2.2 (1.2-4.2) | 0.011 | 2.7 (1.4-5.4) | 0.005 |
IL-4 | 2.4 (1.2-4.6) | 0.014 | 2.3 (1.1-4.5) | 0.018 |
IL-8/CXCL8 | 2.6 (1.4-4.6) | 0.002 | 1.6 (0.9-3.0) | 0.115 |
IL-10 | 2.2 (1.2-4.1) | 0.014 | 2.3 (1.2-4.6) | 0.014 |
TNF-α | 1.6 (0.9-2.8) | 0.104 | 1.5 (0.8-2.6) | 0.202 |
Table 4 Colorectal cancer specific mortality and the association with highest tertile level of inflammatory factors
Factor | CRC specific mortality | CRC specific mortality adjusted1 | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
Age | 1.0 (1.0-1.0) | 0.532 | 1.1 (1.0-1.1) | 0.006 |
TNM stage II | 0.7 (0.1-4.1) | 0.674 | 0.5 (0.1-3.0) | 0.444 |
TNM stage III | 2.6 (0.6-11.7) | 0.201 | 2.7 (0.6-12.9) | 0.209 |
TNM stage IV | 15.5 (3.6-66.3) | < 0.001 | 27.6 (5.8-131.1) | < 0.001 |
Radical surgery | 0.2 (0.1-0.5) | 0.001 | 0.19 (0.1-0.5) | 0.001 |
Preoperative treatment | 0.5 (0.2-1.2) | 0.106 | 0.4 (0.1-0.9) | 0.359 |
Adjuvant treatment | 2.2 (1.2-4.2) | 0.013 | 0.9 (0.5-2.0) | 0.947 |
CCL1 | 3.2 (1.4-7.0) | 0.004 | 2.8 (1.1-7.1) | 0.025 |
CCL3 | 2.4 (1.1-5.3) | 0.036 | 1.2 (0.5-2.8) | 0.653 |
CCL15 | 2.8 (1.3-6.1) | 0.011 | 2.0 (0.9-4.9) | 0.107 |
CCL20 | 4.0 (1.6-10.1) | 0.003 | 2.7 (1.0-7.0) | 0.046 |
CCL24 | 2.2 (1.0-4.8) | 0.061 | 2.5 (1.1-5.7) | 0.037 |
CX3CL1 | 3.7 (1.6-8.3) | 0.002 | 2.6 (1.1-6.4) | 0.036 |
CXCL16 | 2.5 (1.1-5.4) | 0.022 | 2.0 (0.8-4.8) | 0.138 |
IFN-γ | 1.8 (0.8-3.9) | 0.138 | 1.7 (0.7-4.1) | 0.253 |
IL-1β | 1.9 (0.9-3.8) | 0.090 | 1.7 (0.8-3.6) | 0.193 |
IL-4 | 2.5 (1.1-5.7) | 0.033 | 2.4 (1.0-5.5) | 0.048 |
IL-8/CXCL8 | 3.3 (1.5-7.3) | 0.003 | 1.5 (0.6-3.5) | 0.344 |
TNF-α | 2.0 (0.9-4.2) | 0.078 | 2.3 (1.0-5.4) | 0.047 |
Table 5 Inflammatory factors not associated with colorectal cancer specific or total mortality
Factor | Factor |
CCL2 | CCL27 |
CCL7 | CXCL2 |
CCL8 | CXCL5 |
CCL11 | CXCL6 |
CCL13 | CXCL9 |
CCL17 | CXCL11 |
CCL19 | CXCL12 |
CCL21 | GM-CSF |
CCL22 | IL-6 |
CCL23 | IL-16 |
CCL25 | MIF |
CCL26 |
- Citation: Olsen RS, Nijm J, Andersson RE, Dimberg J, Wågsäter D. Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer. World J Gastroenterol 2017; 23(34): 6212-6219
- URL: https://www.wjgnet.com/1007-9327/full/v23/i34/6212.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i34.6212